The interferon-inducible double-stranded (ds) RNA-activated protein kinase (PKR) exhibits antiviral, anticellular, and antitumor activities. The mechanisms of its enzymatic activation by autophosphorylation and of the observed transdominant inhibitory phenotype of enzymatically inactive mutants have invoked PKR dimerization. Here we present direct evidence in support of PKR-PKR interaction. We show that radiolabeled PKR can specifically interact with matrix-bound unlabeled PKR in the absence of dsRNA. The self-association activity resides, in part, in the N-terminal region of 170 residues, which also constitutes the dsRNAbinding domain (DRBD). DRBD can bind to matrix-bound PKR or to matrix-bound DRBD. Dimerization of DRBD was directly demonstrated by chemical crosslinking. Affinity chromatography and electrophoretic mobility supershift assays demonstrated that mutants that fail to bind dsRNA can still exhibit protein-protein interaction. The PKR-PKR interaction could also be observed in a two-hybrid transcriptional activation assay in mammalian cells and consequently is likely to be an important feature of PKR activity in vivo.
activity can still be activated by heparin in vitro (9) and by other unknown activators in vivo (10) . What is common between the various activation processes, however, is autophosphorylation of PKR. Activation of PKR by any activator causes its autophosphorylation and renders PKR enzymatically active and able to phosphorylate other proteins such as the translation initiation factor eIF-2a (11) (12) (13) and the transcriptional inhibitory factor IKB (14) . Although the mechanism of activatorinduced autophosphorylation of PKR is unclear, evidence has been presented to suggest that intermolecular phosphorylation can occur between two PKR molecules (15, 16) .
The most well-studied cellular effect of PKR is inhibition of translation as a result of phosphorylation of eIF-2a, which inhibits its function in translation initiation (17, 18) . dsRNA production during the replication cycle of many viruses triggers this pathway by activating PKR. Since the resultant translational inhibition is detrimental to viral protein synthesis, many viruses have evolved strategies to inhibit PKR action (19, 20) . These strategies include production of other dsRNAbinding proteins (21, 22) , production of decoy substrates with structural similarity to eIF-2a (23) , production of RNAs that inhibit PKR activation (24, 25) , sequestration of PKR (26) , degradation of PKR (27) , and induction of cellular inhibitors of PKR (28) . In addition to its role in cellular immunity against viruses, PKR has been implicated in several other cellular processes. PKR is thought to be involved in the signal transduction process leading to transcriptional induction of some cellular genes by dsRNA (29) (30) (31) . One mechanism of such involvement is by promoting activation of the transcription factor NFKB. Targeted ablation of PKR has been shown to prevent cellular activation of NFKB in response to dsRNA (32) . The activation of NFKB is a result of dissociation of IKB, which is phosphorylated by dsRNA-activated PKR (14) . PKR may also be involved in the control of cell growth (5) and differentiation (33, 34) . Overexpression of enzymatically active PKR has been shown to be growth suppressive in mouse (35) , insect (36) , and yeast cells (5) . On the other hand, expression of catalytically inactive mutants of PKR transforms mouse cells (35, 37) . Cells expressing such mutants can grow in soft agar and form tumors in nude mice. The mutant PKR has been postulated to inhibit the action of normal cellular PKR, which may act as a tumor suppressor protein. The proposed mechanism of transdominant inhibition of PKR by an enzymatically inactive PKR mutant has invoked PKR dimerization. Thus, the postulated mechanisms for PKR autophosphorylation and the observed tumor-promoting activity of inactive PKR mutants require that PKR interacts with itself. The PKR-PKR interaction either may be mediated by dsRNA or may be a result of direct protein-protein interaction. If the interaction is mediated by dsRNA, mutants lacking dsRNA-binding activity are expected to be defective in PKR-PKR interaction.
In this paper, we provide direct experimental evidence for such PKR-PKR interaction. Here we demonstrate direct PKR-PKR interaction mediated in part by the same domain to which dsRNA binds. The dsRNA-binding and the dimerization properties of PKR are, however, distinct and dissociable. The PKR-PKR interaction observed in vitro could also be demonstrated in vivo by using a two-hybrid transcriptional activation assay. These results, therefore, support an intermolecular autophosphorylation mechanism for PKR activation and suggest that the transdominant inhibition by inactive mutants occurs through the formation of inactive heterodimers.
METHODS
Purification of hisK296R, hisDRBD, hisK60A, and his2'5'-Oligoadenylate Synthetase. Plasmids pK296R/pETl5b and DRBD/pETl5b were constructed such that there is an inframe fusion of K296R (3) and DRBD (4) sequences to the histidine tag coding sequences from pETl5b (Novagen). The constuction of K60A/pET15b was as described (38) . The expression and purification of histidine-tagged proteins were done as described (39, 40) . The K60A mutant protein was Proc. Natl. Acad. Sci. USA 92 (1995) further purified by gel filtration chromatography on a Superose-12 FPLC column (Pharmacia).
In Vitro Transcription and Translation. The in vitro transcription and translation of PKR and the truncated PKR proteins were done using the coupled rabbit reticulocyte in vitro translation kit from Promega (9) .
In Vitro Protein-Protein Interaction Assay. The proteins were in vitro translated from 2 ,ug of plasmid DNA using the coupled rabbit reticulocyte in vitro translation kit from Promega. Four microliters of the translation mix was incubated with 1 ,ug of either hisDRBD or hisK296R and 20 ,ul of Ni-charged His-Bind resin at 30°C for 2 hr in binding buffer [5 mM imidazole/200 mM NaCl/20 mM Tris HCl, pH 7.9/0.5% Nonidet P-40 (NP-40)]. After binding, the beads were washed with 500 ,ll of wash buffer (60 mM imidazole/200 mM NaCl/20 mM Tris-HCl pH 7.9/0.5% NP40) six times. The washed beads were then boiled in 2x Laemmli buffer (150 mM Tris HCl, pH 6.8/5% SDS/5% 2-mercaptoethanol/20% glycerol) for 2 min and analyzed by SDS/polyacrylamide gel electrophoresis (SDS/PAGE) on a 12% gel. Fluorography was performed at -80°C with intensifying screens.
Chemical Crosslinking with Dimethyl Suberimidate (DMS). The purified DRBD was dialyzed against 2000 vol of buffer (20 mM Hepes, pH 7.5/10% glycerol) at 4°C for 17 hr. Four micrograms of DRBD was then crosslinked in 100Mul with 1 mM DMS in crosslinking buffer (10 mM Hepes, pH 8.0/100 mM NaCl) at 25°C for 2 hr. Aliquots (10 ,ul) were removed at times indicated and the reaction was stopped by adding 1 M glycine to a concentration of 100 mM. Protein was then denatured by boiling in Laemmli buffer for 2 min and analyzed by SDS/PAGE on a 12% gel followed by Western blot analysis using a polyclonal antibody raised against bacterially produced DRBD (40).
dsRNA-Binding Assay. The polyI-polyC binding assay was performed with 35S-labeled proteins as described (4) .
Electrophoretic Mobility Shift Analysis. The mobility shift analysis of dsRNA was performed as described (40, 41) .
Transfections. The VP16/K296R and VP16/DRBD were constructed by joining the filled-in 1.6-kb or 525-bp Nde I-BamHI fragment from K296R/pETlSb or DRBD/pETlSb to filled-in EcoRI-cut pVP16AASV19N (42) . The GAL4/ K296R and GAL4/DRBD were constructed by joining the filled-in 1.6-kb or 525-bp Nde I-BamHI fragment from K296R/pETlSb or DRBD/pETlSb to Sma I-cut pSG424 (42) .
COS-1 cells were transfected with 200 ng of each of the four (two test plasmids encoding proteins to be tested, the reporter plasmid pGSLuc, and pRSV-f3-galactosidase plasmid to normalize the transfection efficiency) plasmid DNAs by the Lipofectamine procedure as described by the manufacturer (GIBCO/BRL). Cells were harvested 48-hr after transfection and assayed for luciferase activity after normalizing for the transfection efficiency by measuring the ,B-galactosidase activity.
RESULTS
Demonstration of PKR-PKR Interaction by Affinity Chromatography. To determine whether PKR can bind to itself, we performed affinity chromatography using bacterially expressed hexahistidine-tagged enzymatically inactive K296R mutant (PKRM). Since wild-type (wt) PKR is toxic to Escherichia coli and cannot be produced in large quantities, we used the enzymatically inactive K296R mutant in these experiments. Hexahistidine-tagged PKRM was bound to nickel-Sepharose and in vitro translated labeled PKR was tested for binding to PKRM-Sepharose (Fig. 1) . Full-length PKR bound specifically to PKRM-Sepharose (lane 3). It did not bind to uncharged Ni-Sepharose (lane 2) or to Sepharose to which another dsRNA-binding protein, hexahistidine-tagged 2'5' AS, had been bound (lane 4). Another in vitro translated protein, luciferase, did not bind to either uncharged Ni-Sepharose or PKRM-Sepharose (lanes 5-7). These results established that the observed binding of PKR to PKRM-Sepharose was specific for the labeled protein and the matrix-bound protein. It should be noted that about 40% of radiolabeled PKR bound to the affinity matrix. This could be due to partial self-association of in vitro translated PKR before it was exposed to PKRMSepharose or due to incomplete folding of the protein to the self-associating conformation. Nonetheless, the data shown in Fig. 1 demonstrated that PKR can specifically bind to itself.
Multiple Domains Contribute to PKR-PKR Interaction. We used the affinity matrix binding assay of in vitro translated PKR to map the self-binding domains. We expressed various PKR-derived proteins in vitro and tested their abilities to bind to PKRM-Sepharose. These experiments were done under conditions of excess affinity resin. The N-terminal fragment containing residues 1-170 bound to PKRM, although its binding was less efficient than full-length PKR ( Fig. 2A) . Elimination of 68 residues from the C terminus of 1-170 protein completely abolished its binding. The protein containing residues 35-371 bound efficiently as did the protein containing residues 146-551. Another protein containing residues 146-239, on the other hand, failed to bind to PKRM-Sepharose. The binding data (summarized in Fig. 2B ) indicate that PKR contains more than one self-association domain. One of these domains resides within the N-terminal 170 residues with a C-terminal limit between residues 102 and 170 and an Nterminal limit downstream of residue 35 Dimerization of DRBD. The self-association properties of the N-terminal domain comprising residue 1-170 containing the DRBD of PKR (4) were further investigated using hexahistidine-tagged DRBD expressed in bacteria and purified by affinity chromatography. The purified DRBD was 95% pure as judged by silver staining analysis (40) . In vitro translated DRBD was able to specifically bind to PKRM-Sepharose and DRBD-Sepharose (Fig. 3A) . Thus, the N-terminal domain of PKR can associate with itself.
The above conclusion was further supported by exposing the purified bacterially produced DRBD to DMS, a protein crosslinking agent (43) , for different lengths of time followed by analysis by SDS/PAGE (Fig. 3B) . As expected, the untreated protein migrated as a monomer of apparent Mr 22,000. Increasing lengths of exposure to DMS resulted in the formation of increasing amounts of a protein whose mobility was what is expected of a dimeric DRBD of Mr 45,000. Even after prolonged incubation with DMS, however, no larger complexes were observed. These results convincingly demonstrated that DRBD exists in solution primarily as dimeric molecules.
Dissociation of the Dimerization and the dsRNA-Binding Properties. Since a part of PKR's self-association activity is mediated by the same domain that binds dsRNA, we were curious to determine if the same structural motifs within this domain are responsible for both activities. To test this, a mutant PKR, whose residue 60 had been mutated from Lys to Ala, resulting in the loss of its ability to bind to dsRNA (38) , was chromatographed on PKRM-Sepharose. The results (Fig.  4A) show that this mutant retains its ability to bind to PKRM.
The same was also true for the 35-371 derivative of wt-PKR (Fig.   24 ), which has previously been shown to lack the dsRNA-binding ability (4) . These data clearly show that the dimerization and the dsRNA-binding properties of PKR are distinct. The same conclusion is true for the DRBD. Thus, an N-terminally truncated DRBD, containing residues 35-170, could still bind to PKRm, although it failed to bind to dsRNA (Fig. 4A) .
To confirm DRBD-PKR interactions we also employed an electrophoretic mobility shift assay using a radiolabeled 82-bp dsRNA whose mobility was retarded upon its interaction with DRBD or PKR (Fig. 4B) transactivation domain of the VP16 protein of herpes simplex virus. These two plasmids were cotransfected in monkey COS-1 cells along with a reporter plasmid in which the luciferase gene is under the control of a GAL4-binding site and the synthesis of luciferase was assayed by measuring its enzyme activity (Fig. 5) . Transfection of GAL4-PKRM, VP16-PKRM, GAL4-DRBD, or GAL4 and VP16 along with the reporter plasmid resulted in a low level of luciferase production. This level was increased by about 5-fold when GAL4-PKRM and VP16-PKRM were cotransfected. DRBD showed interaction with itself as well as with PKRM. An 18-fold stimulation was observed with GAL4-DRBD and VP16-DRBD and 6-fold stimulation was observed when GAL4-DRBD was cotransfected with VP16-PKRM or GAL4-PKRM was cotransfected with VP16-DRBD. The DRBD-DRBD interaction in vivo was stronger than the PKR-PKR interaction, which could be due to a higher level of expression or more efficient folding of DRBD fusion proteins as compared to the PKR fusion proteins. Quantitatively, the magnitude of this interaction was about half of that observed for the interaction between RAP74 and RAP30, the two subunits of the transcription initiation factor TFIIF (42) . These results, nonetheless, clearly demonstrated that PKR and DRBD can self-associate in the environment of a mammalian cell. DISCUSSION
The mechanisms of PKR activation and phenotypes resulting from overexpression of mutant forms in mammalian cells have led to suggestions that PKR must dimerize to be active. In this investigation we have used four independent assays to provide direct evidence in support of PKR oligomerization. First, the affinity chromatography data not only demonstrated that PKR can interact with itself but also led to the conclusion that there must be more than one interaction domain on the molecule. The N-terminal domain, which partially overlaps with the DRBD and which contains at least one interaction domain, was studied in more detail. Second, direct chemical crosslinking of the DRBD demonstrated that this domain can form dimers. In view of this result, it is worth noting that DRBD can inhibit the activity of purified PKR (40) . It was observed that when added to monoclonal antibody-bound PKR, DRBD could inhibit its kinase activity even at concentrations that are not sufficient to soak up the activator dsRNA. Inhibition at these low DRBD concentrations can be explained by DRBD-PKR interaction leading to inactivation of PKR activity. These results suggest that PKR may also exist as dimers, although thus far there is no direct experimental evidence for this. Attempts to crosslink PKRM resulted in large oligomeric complex formation (data not shown) whose physiological significance remains to be evaluated. There is information in the literature, however, suggesting PKR dimer formation. Size fractionation of PKR partially purified from a mouse cell extract showed that a part of the PKR pool has the apparent molecular weight of a dimer (45) .
The third approach to demonstrate a protein-protein interaction between PKR and DRBD was adapted from the techniques commonly used for studying DNA-protein interactions. To confirm the presence of an alleged protein in a shifted DNA-protein complex, a specific antibody to the protein is added to the mixture. The antibody binds to the protein-DNA complex and retards its mobility further causing a "supershifting." We used the same principle to demonstrate that a mutant PKR, which cannot bind dsRNA, could supershift DRBD-dsRNA complexes. Thus, the interaction must be directly between the two proteins. This and other results also established clearly that the dsRNA-binding and the dimerization properties of PKR are separable. Mutants defective in dsRNA binding could still dimerize. Whether the converse is also true will have to await a more accurate definition of the dimerization domain. In the case of another RNA-binding protein, human immunodeficiency virus type 1 rev (46, 47) , several mutants defective in RNA binding can still dimerize. rev mutants defective in oligomerization, however, fail to bind RNA, indicating that the RNA-binding domain may be formed Dimerization of PKR has been suggested as a possible mechanism for its autophosphorylation (15, 16, 48) . It is known that dsRNA binding causes PKR autophosphorylation. Phosphorylated PKR is an active kinase that can phosphorylate substrates, such as eIF-2a, in the absence of dsRNA. The autophosphorylation reaction kinetics suggest that it is an intermolecular reaction (15) that, by definition, requires a close proximity of two PKR molecules. Binding of two PKR molecules to the same dsRNA molecule may promote such juxtaposition, thus explaining the basis of PKR activation by dsRNA. Alternatively, PKR may exist as dimers prior to its activation by dsRNA, as suggested by the evidence presented in this paper. In this scenario, dsRNA or other activators of PKR change its conformation to an active state so that it can phosphorylate its bound partner. Experimental evidence presented in this paper strongly favors the second model. It may also explain how small molecules such as heparin, which are unlikely to bind two PKR molecules simultaneously, can promote phosphorylation of PKR. The observed loss of the activator effect of dsRNA at a high concentration can be explained by postulating that if two dsRNA molecules can bind to the two partners of a PKR dimer, the two monomers are pulled apart because their affinity for dsRNA is much higher than their mutual affinity.
Much of the information in the literature in support of various cellular roles of PKR has come from the use of enzymatically inactive mutants of PKR. Studies using this approach have indicated antiviral (49) , antiproliferative (6, 36, 37) , and transcriptional signal transducer roles of PKR (ref. 14; R.C.P. and G.C.S., unpublished observations). More dramatically, it has been shown that cells expressing PKR inactive mutants are highly tumorigenic (35, 37) , thus suggesting that PKR may be a tumor suppressor (12) . Although these observations are well documented, the underlying mechanism of action of the inactive PKR mutants remains unclear. Three, not mutually exclusive, possibilities exist that all lead to the inactivation of cellular PKR. The inactive mutants may sequester the natural cellular activators of PKR (50) , which may or may not be dsRNA. They may also sequester the potential substrates of PKR, such as eIF-2a and IKB, thereby protecting them from being phosphorylated by PKR. Finally, they may act as a trans-dominant inhibitor of PKR by forming heterodimers. For the third mechanism to operate, such heterodimers containing one active PKR molecule and one inactive PKR molecule should be enzymatically impaired for phosphorylating cellular substrates, a postulation yet to be demonstrated. This third model of heterodimer formation has been widely used to explain the observed trans-dominant inhibition by inactive mutants of PKR. This paper provides strong experimental support in favor of the heterodimerization model. Our experiments demonstrated PKR-PKR, PKR-DRBD, and DRBD-DRBD interactions in vitro and in vivo. The final test of the heterodimerization model for explaining trans-dominance of inactive PKR in vivo will come from examining the phenotypes of PKR mutants that fail to dimerize but still bind the activators and the known substrates.
